A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hairfolliclecell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
Hair cloning and injection of dermalpapillacells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
HairClone is offering a DermalPapillaCellHair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
AMP-303 and AMP-601 are new hair loss treatments targeting dermalpapillacells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.